Gyre Therapeutics (GYRE) Preferred Stock Liabilities (2012 - 2023)
Gyre Therapeutics (GYRE) reported Preferred Stock Liabilities of $64.5 million for Q4 2023, up 93.72% year-over-year from $33.3 million in Q4 2022, and up 93.72% on a QoQ basis from $33.3 million in Q2 2023.
Gyre Therapeutics (GYRE) has 5 years of Preferred Stock Liabilities data on file, last reported at $64.5 million in Q4 2023.
- Quarterly Preferred Stock Liabilities rose 93.72% year-over-year to $64.5 million in Q4 2023, while the trailing twelve-month figure through Dec 2023 was $64.5 million (up 93.72% YoY) and the FY2023 annual result came in at $64.5 million, up 93.72% from the prior year.
- Preferred Stock Liabilities climbed to $64.5 million in Q4 2023 per GYRE's latest filing, from $33.3 million in the prior quarter.
- Across five years, Preferred Stock Liabilities topped out at $64.5 million in Q4 2023 and bottomed at $33.3 million in Q4 2022.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | - |
| 10 | Gyre Therapeutics | 532.38 Mn | 518.25 Mn | 8.38 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 64.53 Mn |
| Jun 30, 2023 | 33.31 Mn |
| Mar 31, 2023 | 33.31 Mn |
| Dec 31, 2022 | 33.31 Mn |
| Dec 31, 2014 | 108.88 Mn |
| Dec 31, 2013 | 104.64 Mn |
| Dec 31, 2012 | 98.90 Mn |